Latanoprost Vir (Latanoprost)

Latanoprost binds to FP receptors in the ciliary body, triggering remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow reduces the fluid volume inside the eye, thereby lowering intraocular pressure.

The dosing regimen for Latanoprost Vir is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and schedule must follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Latanoprost Vir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which is often preferred for its once‑daily dosing and strong IOP‑lowering effect. Compared with beta‑blockers or carbonic anhydrase inhibitors, latanoprost generally provides greater pressure reduction with a convenient dosing schedule, though individual response may vary.

Latanoprost Vir should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light, and avoid freezing. Do not refrigerate unless specifically instructed by the manufacturer.

Latanoprost Vir is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to any surface, and close the eye gently after instillation.

Serious risks, though rare, include severe allergic reactions such as angioedema, ocular inflammation (uveitis), paradoxical increase in intraocular pressure, corneal edema, and sudden vision loss. Patients should seek immediate medical attention if they experience any of these symptoms.

Latanoprost Vir should not be used by individuals with known hypersensitivity to latanoprost or any of its excipients. Caution is advised in pregnant or breastfeeding women, and in patients with active ocular infections or inflammation until these conditions are resolved.